CollPlant Biotechnologies
CLGN
2 hedge funds and large institutions have $781K invested in CollPlant Biotechnologies in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
25% more capital invested
Capital invested by funds: $625K → $781K (+$156K)
0% less ownership
Funds ownership: 0.08% → 0.07% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
33% less funds holding
Funds holding: 3 → 2 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
+$1.21K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIIFS
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
|
-$21.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$14K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MIH
1
Meitav Investment House
Bene-Beraq,
Israel
| $780K | +$1.21K | +227 | +0.2% |
|
|
HIIFS
2
Harel Insurance Investments & Financial Services
Ramat Gan,
Israel
| $1K | -$21.4K | -4,000 | -97% |
|
|
3
UBS Group
Zurich,
Switzerland
| – | -$14K | -3,316 | Closed |
|
CLGN Hedge Fund Activity: Q1 2019 in Review
2 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in CollPlant Biotechnologies (CLGN) for Q1 2019, worth a combined $781K — up 25% from $625K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of CLGN and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Meitav Investment House, adding an estimated $1.21K. The largest seller was Harel Insurance Investments & Financial Services, cutting an estimated $21.4K.
- 2 institutional investors held CollPlant Biotechnologies (CLGN) as of Q1 2019, down from 3 in Q4 2018.
- Funds reported $781K of CollPlant Biotechnologies stock for Q1 2019, up 25% quarter-over-quarter.
- 0 funds opened new CollPlant Biotechnologies positions in Q1 2019 and 1 closed out, a net change of -1 holder.
- The largest CollPlant Biotechnologies buyer in Q1 2019 was Meitav Investment House, an estimated $1.21K added.
- The largest CollPlant Biotechnologies seller in Q1 2019 was Harel Insurance Investments & Financial Services, an estimated $21.4K sold.
Based on aggregated 13F filings for Q1 2019.